Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind study of TST002 in postmenopausal osteoporosis and low bone mass
CTR20263709Phase 2Active
- Sponsor
- TransThera Biosciences
- Start
- Oct 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of blosozumab in postmenopausal osteoporosis, osteopenia, sponsored by TransThera Biosciences. Started Oct 2026; status: active.
02
Drugs
blosozumab
03
Conditions
postmenopausal osteoporosisosteopenia
Beyond the preview
Go deeper on CTR20263709.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263709.